MedTrace Logo

Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma

NCT04136886 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 346

Last updated 2019-10-23

No results posted yet for this study

Summary

The purpose of this study is to determine whether concurrent chemotherapy and IMRT is effective in the treatment of locally stage T3/T4 recurrent nasopharyngeal carcinoma patients compared with IMRT alone.

Conditions

  • Nasopharyngeal Carcinoma

Interventions

DRUG

Cisplatin

cisplatin is to give from the first Day of radiation therapy D1,D22 Q3W for 2 cycles Radiation: IMRT IMRT is to give 60Gy in 27 fraction

RADIATION

IMRT

Radiation: IMRT IMRT is to give 60Gy in 27 fraction

Sponsors & Collaborators

  • JiangXi Province Tumor Hospital

    collaborator UNKNOWN

  • Fujian Province Tumor Hospital

    collaborator OTHER

  • SiChuan Province Tumor Hospital

    collaborator UNKNOWN

  • Hunan Province Tumor Hospital

    collaborator OTHER

  • YuNan Province Tumor Hospital

    collaborator UNKNOWN

  • GuiZhou Province Tumor Hospital

    collaborator UNKNOWN

  • Hainan Cancer Hospital

    collaborator OTHER

  • Tongji Hospital

    collaborator OTHER

  • Second Affiliated Hospital of Nanchang University

    collaborator OTHER

  • Wuhan University

    collaborator OTHER

  • First Hospital of FoShan City

    collaborator UNKNOWN

  • Sun Yat-sen University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04136886 on ClinicalTrials.gov